Document is current
Any future updates will be listed below
-
Authors
Gold, Michael https://orcid.org/0000-0002-5183-5433
Lain, Ted
Harper, Julie C.
Baldwin, Hilary
Guenin, Eric
Stein Gold, Linda
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03170388 at ClinicalTrials.govnct04892706 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity
https://doi.org/10.1007/s13555-025-01440-z
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
https://doi.org/10.1007/s40257-021-00650-3
nct04214639 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity
https://doi.org/10.1007/s13555-025-01440-z
nct04214652 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity
https://doi.org/10.1007/s13555-025-01440-z
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis
https://doi.org/10.1007/s13555-024-01155-7
Documents that mention this clinical trial
Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity
https://doi.org/10.1007/s13555-025-01440-z
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis
https://doi.org/10.1007/s13555-024-01155-7
-
Funding
Funding for this research was provided by:
Ortho Dermatologics
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 25 April 2025
First Online: 16 May 2025
Declarations
:
: Michael Gold has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics and is an Editorial Board member of Dermatology and Therapy. Michael Gold was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Edward Lain has served as investigator, consultant and/or speaker for Ortho Dermatologics, AbbVie, Almirall, Amgen, Arcutis, Dermavant, EPI Health, Galderma, Incyte, LEO Pharma, Novartis, Eli Lilly, Pfizer, Sun Pharma, UCB, Endo International, ChemoCentryx, Biorasi, Sirnaomics, Evelo Biosciences, Concert Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Mindera, Biofrontera, Alfasigma, AiViva Biopharma, Anaptys Bio, Bausch Health, Dr Reddy’s, and Trevi Therapeutics. Julie Harper has received honoraria from Almirall, Galderma, LaRoche-Posay, Ortho Dermatologics, and Sun Pharma. Hilary Baldwin has served as advisor, investigator, and on speakers bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. Linda Stein Gold has served as investigator/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis, and Lilly. Eric Guenin is an employee of Ortho Dermatologics and may hold stock and/or stock options in its parent company.
: All studies were carried out in accordance with principles of Good Clinical Practice and the Declaration of Helsinki. Study protocols for the phase 2 studies were approved by Quorum (Seattle, WA, USA; reference number 32733), Henry Ford Health System IRB (Detroit, MI, USA), Research Review Board-Canada (Richmond Hill, Ontario, Canada; reference number 2017.484), Sterling IRB (Atlanta, GA, USA; reference number 8817-*MASTER), Commissie Medische Ethiek AZ Groeninge (Kortrijk, West Flanders, Belgium), and Biomedical Research Ethics Board (Winnipeg, Manitoba, Canada). Study protocols across all study centers for the phase 3 studies were approved by the same central institutional review board (Advarra IRB, Columbus, MD, USA; reference numbers Pro00040366 and Pro00040925). Investigator names are listed in Supplementary Material Table . All participants or their legal guardians provided written informed consent before entering the clinical trials in which the data were generated. Additional informed consent was obtained from all individual participants for whom identifying information/photographs are included in this article.
